Alkermes plc filings document a Nasdaq-listed Irish public limited biopharmaceutical company focused on neuroscience medicines. The record includes 8-K reports for operating results, financial expectations, investor presentations, material definitive agreements and Regulation FD disclosures, along with proxy materials for annual general meeting matters, director elections, executive compensation and shareholder voting.
Capital-structure disclosures cover ordinary shares listed under ALKS and senior secured term loan facilities used in connection with completed acquisition activity. Material-event reports also address governance and executive transition matters, compensatory arrangements, commercial-product performance and clinical-stage disclosures for the company’s orexin 2 receptor agonist programs.
Alkermes plc. director Richard Gaynor reported routine equity compensation and related share movements. He exercised 6,142 restricted stock units into ordinary shares and had 1,475 shares withheld to cover tax obligations at $36.95 per share, leaving 35,751 ordinary shares directly held after the withholding.
Gaynor also received new awards on ordinary shares: 5,409 restricted stock units and 11,538 non-qualified stock options with a $36.98 exercise price. Both the new RSUs and options vest fully on May 20, 2027, and the option award is exercisable after vesting through May 20, 2036.
Alkermes plc director Shane Cooke reported routine equity compensation activity and related tax withholding. He exercised 6,142 restricted stock units into ordinary shares and had 3,207 shares withheld to cover tax obligations at a price of $36.95 per share, which is not an open-market sale.
Cooke also received new awards on May 20, 2026, including 5,409 restricted stock units and a non-qualified stock option for 11,538 ordinary shares with an exercise price of $36.98 per share, both vesting in full on May 20, 2027. Following these transactions, he holds 109,886 ordinary shares directly.
Alkermes plc reported results from its 2026 annual general meeting of shareholders. Investors approved amendments to the 2018 Stock Option and Incentive Plan, increasing the ordinary shares authorized for issuance under the plan by 5,900,000. The updated plan is filed as Exhibit 10.1.
Shareholders elected all nine director nominees for one-year terms, with each receiving over 135 million votes in favor in most cases. They also approved, in a non-binding advisory vote, the compensation of named executive officers and ratified the appointment of PricewaterhouseCoopers LLP as independent auditor, authorizing the Audit and Risk Committee to set its remuneration.
In addition, shareholders renewed the Board’s authority to allot and issue shares under Irish law and renewed authority to disapply statutory pre-emption rights. Overall, the meeting confirmed the company’s current board composition, executive pay program, equity incentive plan, and capital authorization framework.
ALKERMES PLC reported a Schedule 13G/A amendment showing T. Rowe Price Associates, Inc. beneficially owned 4,664,563 shares of Common Stock, representing 2.8% of the class as stated in the filing. The filing lists sole voting power of 4,650,687 shares and sole dispositive power of 4,664,563. The report is signed by Ellen York, Vice President, dated 05/15/2026.
Alkermes plc reported positive phase 3 topline results from the REVITALYZ study of once-nightly LUMRYZ in adults with idiopathic hypersomnia. LUMRYZ met the primary endpoint, showing statistically significant improvement in excessive daytime sleepiness versus placebo on the Epworth Sleepiness Scale (p<0.0001), and met key secondary endpoints PGI-C and IHSS with similar significance.
The safety profile in idiopathic hypersomnia was generally consistent with prior LUMRYZ data, with common adverse events including nausea, headache, anxiety, dizziness and vomiting. Alkermes plans to submit a supplemental New Drug Application to the U.S. FDA by the end of 2026, but under an existing settlement it cannot market LUMRYZ for idiopathic hypersomnia before March 1, 2028, even if approved.
Alkermes plc reported a quarterly net loss after completing a large acquisition. For the three months ended March 31, 2026, revenue rose to $392.9 million from $306.5 million, driven by higher product sales including LUMRYZ, which contributed $39.5 million after the Avadel Pharmaceuticals acquisition.
The company recorded a net loss of $66.5 million, or $0.40 per share, compared with net income of $22.5 million a year earlier, mainly due to higher R&D, selling, general and administrative costs, amortization of new intangibles, and increased interest expense tied to new debt.
Alkermes closed the Avadel deal for about $2.31 billion in total preliminary consideration, recognizing $513.0 million of goodwill and $1.79 billion of intangible assets. To fund the transaction, it drew $1.525 billion of new term loans, which increased total assets to $4.26 billion and reduced cash and cash equivalents to $351.6 million.
Alkermes plc reported strong top-line growth but a GAAP loss for Q1 2026 and raised its EBITDA outlook for the year. Total revenues rose to $392.9 million from $306.5 million, driven by proprietary net sales of $338.1 million, including LYBALVI $92.4 million, ARISTADA $93.8 million, VIVITROL $112.4 million and newly acquired LUMRYZ $39.5 million.
The company posted a GAAP net loss of $66.5 million versus GAAP net income of $22.5 million a year earlier, with EBITDA at $(30.1) million and Adjusted EBITDA improving to $80.3 million from $45.6 million. Alkermes closed its acquisition of Avadel Pharmaceuticals in February, using about $775 million of cash and entering into $1.525 billion of term loans due 2031, leaving cash, cash equivalents, restricted cash and investments at $538.2 million versus $1.32 billion at year-end 2025.
For 2026, total revenue guidance of $1.73–$1.84 billion is unchanged, but GAAP net loss expectations improved to $70–$90 million and EBITDA guidance increased to $105–$135 million, while Adjusted EBITDA remains targeted at $370–$410 million. The outlook assumes VIVITROL net sales of $460–$480 million, LYBALVI $380–$400 million, ARISTADA $365–$385 million and LUMRYZ $315–$335 million.
Alkermes plc executive David Joseph Gaffin, EVP and Chief Legal Officer of Alkermes, Inc., reported an open-market sale of 2,034 Ordinary Shares at $33.20 per share. The transaction was made under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person. Following this sale, he continues to hold 231,558 Ordinary Shares directly, indicating a substantially larger remaining equity position in the company.
Alkermes plc officer David Joseph Gaffin reported a proposed sale of 2,034 common shares, with an aggregate market value of 67,528.80 and an approximate sale date of May 4, 2026. Merrill Lynch is listed as broker, and the notice gives November 19, 2025 as the Rule 10b5-1 plan adoption or instruction date. It also lists three earlier sales of 2,034 shares each: March 2 for 59,575.86, March 3 for 60,531.84, and April 6 for 70,315.38 in gross proceeds.
Alkermes plc EVP R&D and Chief Medical Officer Craig C. Hopkinson exercised employee stock options for 5,000 ordinary shares at $19.34 per share and then sold 9,000 ordinary shares at a weighted average price of $33.3955 on May 1, 2026.
Both the option exercise and the open-market sale were carried out under a pre-arranged Rule 10b5-1 trading plan adopted on March 14, 2025. After these transactions, Hopkinson directly held 81,389 ordinary shares, and the exercised options are fully vested in accordance with their terms.